Myotonic dystrophy type 1 in the COVID-19 era.
Ilic-Zivojinovic JelenaKatarina DjurdjevicIvo BozovicGiovanni MeolaMarina PericAna Azanjac ArsicIvana BastaVidosava Rakocevic-StojanovicStojan Z PericPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)
The percentage of DM1 patients who suffered from COVID-19 was like in general population, but with more severe forms in DM1, especially in patients with longer DM1 duration. The study indicated an overall favorable safety profile of COVID-19 vaccines among individuals with DM1 and its ability to protect them from severe COVID-19.